| HOME >> BIOLOGY >> TECHNOLOGY |
Accrued expense for patent-related matter - 3,350
Current portion of deferred revenue 4,016 3,913
Current portion of license fees payable - 447
Current portion of equipment financing - 313
Current portion of note payable 2 11
Total current liabilities 35,566 31,450
Long-term portion of deferred revenue 2,054 2,663
Long-term portion of equipment financing - 3
Long-term portion of note payable 2 41
Deferred rent 688 798
Total liabilities 38,310 34,955
Shareholders' equity:
Common stock 254,807 251,132
Additional paid-in capital 26,697 15,065
Accumulated other comprehensive loss 340 (5)
Accumulated deficit (154,909) (133,486)
Total shareholders' equity 126,935 132,706
Total liabilities and shareholders' equity $165,245 $167,661
Table A - GAAP vs. Non GAAP Measures
Three months ended Year ended
December 31, December 31,
2007 2006 2007 2006
Total Product Sales $36,865 $21,603 $116,532 $82,403
Total Revenues $40,427 $23,582 $129,473 $87,352
Cost of product sales $21,452 $12,443 $69,174 $48,800
Stock compensation expense (264) (53) (794) (584)
Amorti
'/>"/>
| SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved |